Alteration of cellular and humoral immunity by mutant p53 protein and processed mutant peptide in head and neck cancer.
OBJECTIVE
To determine if serologic recognition of p53 mutations at the protein level depends upon the ability of mutant p53 to express new peptide epitopes that bind to human leukocyte antigen (HLA) class II molecules, we used anti-p53 antibody production as a marker for HLA class II-restricted T-cell involvement in head and neck cancer.


METHODS
An anti-p53 antibody response was correlated with specific p53 mutations and the patients' HLA class II alleles and haplotypes. HLA binding studies and in vitro stimulation (IVS) of peripheral blood mononuclear cells were done using a mutant versus wild-type HLA-DQ7-binding p53 peptide.


RESULTS
Certain HLA-DQ and HLA-DR alleles were frequently present in p53 seropositive patients who produced serum anti-p53 antibodies. Selected mutated p53 peptides fit published allele-specific HLA class II binding motifs for the HLA-DQ7 or HLA-DR1 molecules. Moreover, a mutant p53 peptide bound with a 10-fold greater affinity than the wild-type p53 peptide to HLA-DQ7 molecules. IVS of CD4(+) T cells from seven healthy HLA-DQ7(+) donors using this mutant p53 peptide (p53(220C)) was associated with a partial T helper type 2 phenotype compared with IVS using the wild-type p53(210-223) peptide.


CONCLUSIONS
Our results support the hypothesis that mutated p53 neoantigens can bind to specific HLA class II molecules, leading to a break in tolerance. This may lead to skewing of the CD4(+) T lymphocyte response toward a tumor-permissive T helper type 2 profile in head and neck cancer patients, as manifested by seropositivity for p53.
Couch
Marion E
ME
Department of Otolaryngology-Head and Neck Surgery, University of North Carolina, G0412 Neurosciences Hospital, Chapel Hill, North Carolina, USA.
Ferris
Robert L
RL
Brennan
Joseph A
JA
Koch
Wayne M
WM
Jaffee
Elizabeth M
EM
Leibowitz
Michael S
MS
Nepom
Gerald T
GT
Erlich
Henry A
HA
Sidransky
David
D
D000595:Amino Acid Sequence; D000912:Antibodies, Neoplasm / Q000096:biosynthesis / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018985:Epitopes, B-Lymphocyte / Q000276:immunology; D006683:HLA-DQ Antigens / Q000235:genetics / Q000276:immunology; D006684:HLA-DR Antigens / Q000235:genetics / Q000276:immunology; D006258:Head and Neck Neoplasms / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D007371:Interferon-gamma / Q000276:immunology; D015848:Interleukin-5 / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008969:Molecular Sequence Data; D011110:Polymorphism, Genetic; D018418:Th2 Cells / Q000276:immunology; D016159:Tumor Suppressor Protein p53 / Q000235:genetics* / Q000276:immunology*
D000912:Antibodies, Neoplasm; D018985:Epitopes, B-Lymphocyte; D006683:HLA-DQ Antigens; D006684:HLA-DR Antigens; C508599:IL5 protein, human; D015848:Interleukin-5; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D007371:Interferon-gamma